Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Sangamo Therapeutics
(NQ:
SGMO
)
0.8576
-0.0022 (-0.26%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Aug 23, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Sangamo Therapeutics
< Previous
1
2
3
Next >
Sangamo Therapeutics Reports Recent Business Highlights and Second Quarter 2024 Financial Results
August 06, 2024
From
Sangamo Therapeutics, Inc.
Via
Business Wire
Sangamo Therapeutics Announces Global Epigenetic Regulation and Capsid Delivery License Agreement with Genentech to Develop Novel Genomic Medicines for Neurodegenerative Diseases
August 06, 2024
From
Sangamo Therapeutics, Inc.
Via
Business Wire
Sangamo Therapeutics Announces Second Quarter 2024 Conference Call and Webcast
July 30, 2024
From
Sangamo Therapeutics, Inc.
Via
Business Wire
Sangamo Therapeutics Reports on Pfizer’s Announcement of Positive Topline Results From Phase 3 Trial of Hemophilia A Gene Therapy Candidate
July 24, 2024
From
Sangamo Therapeutics, Inc.
Via
Business Wire
Major Potential: 5 NASDAQ / NYSE Stocks Under $1 SGMO, FTCI, VTAK, SPRB, DNA
July 11, 2024
Via
AB Newswire
Sangamo Therapeutics Reports Recent Business Highlights and First Quarter 2024 Financial Results
May 09, 2024
From
Sangamo Therapeutics, Inc.
Via
Business Wire
Sangamo Therapeutics Presents Next-Generation Modular Integrase Technology Engineered to Enable Large-Scale Genome Editing
May 09, 2024
From
Sangamo Therapeutics, Inc.
Via
Business Wire
Sangamo Therapeutics Announces First Quarter 2024 Conference Call and Webcast
May 02, 2024
From
Sangamo Therapeutics, Inc.
Via
Business Wire
Sangamo Therapeutics to Present Neurology-Focused Pre-Clinical Data From Its Epigenetic Regulation, Capsid Delivery and Genome Engineering Platforms at the 27th Annual Meeting of the American Society of Gene & Cell Therapy (ASGCT)
April 22, 2024
From
Sangamo Therapeutics, Inc.
Via
Business Wire
Sangamo Therapeutics Announces Pricing of $24.0 Million Registered Direct Offering
March 22, 2024
From
Sangamo Therapeutics, Inc.
Via
Business Wire
Sangamo Therapeutics Reports Recent Business Highlights and Fourth Quarter and Full Year 2023 Financial Results
March 13, 2024
From
Sangamo Therapeutics, Inc.
Via
Business Wire
Sangamo Therapeutics Announces Data From Novel Proprietary Neurotropic AAV Capsid Demonstrating Industry-leading Blood-brain Barrier Penetration and Brain Transduction in NHPs
March 13, 2024
From
Sangamo Therapeutics, Inc.
Via
Business Wire
Sangamo Therapeutics Announces Fourth Quarter and Full Year 2023 Conference Call and Webcast
March 12, 2024
From
Sangamo Therapeutics, Inc.
Via
Business Wire
Sangamo Therapeutics Announces U.S. FDA Alignment on Abbreviated Pathway to Potential Approval and EMA Prime Eligibility for ST-920 in Fabry Disease
February 12, 2024
From
Sangamo Therapeutics, Inc.
Via
Business Wire
Sangamo Therapeutics Announces Updated Phase 1/2 STAAR Study Data in Fabry Disease Showing Sustained Benefit and Differentiated Safety Profile
February 05, 2024
From
Sangamo Therapeutics, Inc.
Via
Business Wire
2 low-priced gene therapy stocks to speculate on
January 08, 2024
Gene therapy differs from gene editing, which is getting the lion's share of headlines. While gene editing is a form of gene therapy, there are basic diffe
Via
MarketBeat
Exposures
Product Safety
Sangamo Therapeutics Announces Strategic Update and Reports Third Quarter 2023 Financial Results
November 01, 2023
From
Sangamo Therapeutics, Inc.
Via
Business Wire
Sangamo Therapeutics Announces Third Quarter 2023 Conference Call and Webcast
October 25, 2023
From
Sangamo Therapeutics, Inc.
Via
Business Wire
Sangamo Therapeutics to Present Pre-Clinical Data Showcasing Its Epigenetic Regulation for Neurology and CAR-Treg Research at the 30th Annual Congress of the European Society of Gene & Cell Therapy (ESGCT)
October 24, 2023
From
Sangamo Therapeutics, Inc.
Via
Business Wire
Sangamo Therapeutics to Present at the Jefferies Cell & Genetic Medicine Summit
September 20, 2023
From
Sangamo Therapeutics, Inc.
Via
Business Wire
Sangamo Therapeutics Reports Recent Business Highlights and Second Quarter 2023 Financial Results
August 08, 2023
From
Sangamo Therapeutics, Inc.
Via
Business Wire
Sangamo Therapeutics Announces Second Quarter 2023 Conference Call and Webcast
August 01, 2023
From
Sangamo Therapeutics, Inc.
Via
Business Wire
Sangamo Therapeutics and Chroma Medicine Announce Option and License Agreement to Evaluate and Develop Zinc Finger Proteins for Epigenetic Editing
July 20, 2023
From
Sangamo Therapeutics, Inc.
Via
Business Wire
Sangamo Therapeutics Announces Research Evaluation and Option Agreement With Prevail, a Wholly Owned Subsidiary of Lilly, for Novel Engineered Capsids
July 17, 2023
From
Sangamo Therapeutics, Inc.
Via
Business Wire
Sangamo Therapeutics and Voyager Therapeutics Enter License Agreement for Epigenetic Regulation Treatment of Prion Disease
June 29, 2023
From
Sangamo Therapeutics, Inc.
Via
Business Wire
Sangamo Therapeutics Receives U.S. FDA Fast Track Designation for Isaralgagene Civaparvovec for the Treatment of Fabry Disease
May 22, 2023
From
Sangamo Therapeutics, Inc.
Via
Business Wire
Sangamo Therapeutics Announces Appointment of Lisa Rojkjaer, M.D., as Chief Medical Officer
May 16, 2023
From
Sangamo Therapeutics, Inc.
Via
Business Wire
Sangamo Therapeutics to Present Pre-clinical Data From Its Genomic Engineering Platform at the 26th Annual Meeting of the American Society of Gene & Cell Therapy (ASGCT)
May 02, 2023
From
Sangamo Therapeutics, Inc.
Via
Business Wire
Sangamo Therapeutics Announces Strategic Update and Reports Preliminary First Quarter 2023 Financial Results
April 26, 2023
From
Sangamo Therapeutics, Inc.
Via
Business Wire
Sangamo Therapeutics Announces First Quarter 2023 Conference Call and Webcast
April 19, 2023
From
Sangamo Therapeutics, Inc.
Via
Business Wire
< Previous
1
2
3
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.